MarketCapExport financials
iCAD (ICAD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
iCAD Balance Sheet 2024-2008 | ICAD
Brief overview of iCAD's assets and capital
The balance sheet is assessed across five available annual reports spanning 2020 to 2024.
The asset base decreased -32.5%, from $55.6 million to $37.5 million. Resources became smaller over the five periods.
Liabilities grew more slowly than assets: -64.7% versus -32.5%. Expansion relied more on equity, improving funding quality.
The equity ratio reached 76.4% from 54.9%. A high capital share reduces dependence on liabilities.
Net debt moved below zero to -$16.8 million, reflecting surplus cash over debt.
Cash accounts for 45.8% of assets versus 48.9% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$277.3 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
iCAD's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet iCAD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-16.8 M | -21.2 M | -20.6 M | -33.1 M | -20.2 M | 4.58 M | 890 K | -3.45 M | -8.5 M | -14.2 M | -21.6 M | 3.77 M | 898 K | -4.58 M | - | - | - |
Long Term Debt |
133 K | 273 K | 455 K | 266 K | 6.96 M | 15.6 M | 11.2 M | 5.12 M | - | - | 5.6 M | 11.8 M | 14.8 M | - | - | - | - |
Long Term Debt Current |
229 K | 188 K | 217 K | 889 K | - | 795 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 17.8 M | 11.6 M | 5.78 M | 758 K | 1.62 M | 8.94 M | 15.1 M | 17.7 M | 3.22 M | - | - | - |
Total Current Liabilities |
7.56 M | 6.75 M | 13.5 M | 15 M | 16.8 M | 18.8 M | 13.2 M | 12.1 M | 12.9 M | 14.3 M | 22 M | 22.5 M | 14.6 M | 12.5 M | 13.3 M | - | - |
Total Liabilities |
8.86 M | 8 M | 16.8 M | 15.7 M | 25.1 M | 36.7 M | 24.8 M | 17.9 M | 13.6 M | 15.9 M | 31 M | 37.5 M | 32.3 M | 15.7 M | 22.4 M | - | - |
Deferred Revenue |
3.86 M | 3.4 M | 3.65 M | 5.65 M | 6.12 M | 5.25 M | 5.16 M | 5.4 M | 5.37 M | 7.5 M | 9.12 M | 8.31 M | 6.52 M | 5.76 M | 4.91 M | - | - |
Retained Earnings |
-277 M | -272 M | -267 M | -253 M | -242 M | -224 M | -211 M | -202 M | -188 M | -178 M | -145 M | -144 M | -136 M | -127 M | -89.5 M | - | - |
Total Assets |
37.5 M | 41.4 M | 51.7 M | 62.2 M | 55.6 M | 41.7 M | 31.7 M | 32.1 M | 38.7 M | 48.6 M | 93.8 M | 58.9 M | 60 M | 51.8 M | 95.6 M | - | - |
Cash and Cash Equivalents |
17.2 M | 21.7 M | 21.3 M | 34.3 M | 27.2 M | 15.3 M | 12.2 M | 9.39 M | 8.58 M | 15.3 M | 32.2 M | 11.9 M | 13.9 M | 4.58 M | 16.3 M | 16.2 M | 13.1 M |
Book Value |
28.7 M | 33.4 M | 34.9 M | 46.5 M | 30.5 M | 5.07 M | 6.9 M | 14.3 M | 25 M | 32.7 M | 62.8 M | 21.4 M | 27.7 M | 36.1 M | 73.2 M | - | - |
Total Shareholders Equity |
28.7 M | 33.4 M | 34.9 M | 46.5 M | 30.5 M | 5.07 M | 6.9 M | 14.3 M | 25 M | 32.7 M | 62.8 M | 21.4 M | 27.7 M | 36.1 M | 73.2 M | 66.3 M | 66.3 M |
All numbers in USD currency
Quarterly Balance Sheet iCAD
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
73 K | 133 K | 191 K | 249 K | - | 273 K | 317 K | 2.48 M | 2.64 M | 2.8 M | 2.48 M | 2.6 M | 54 K | 266 K | 431 K | 646 K | 860 K | 1.08 M | 1.29 M | 1.5 M | 1.71 M | 1.84 M | 1.55 M | 3 K | 8 K | 38 K | 38 K | 38 K | 38 K | - | 5.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.68 M | 8.86 M | 7.73 M | 7.98 M | - | 8 M | 14.8 M | 14.7 M | 15.8 M | 16.8 M | 17.7 M | 17.4 M | 15.1 M | 15.7 M | 15.9 M | 15.5 M | 22.1 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 36.7 M | 36.7 M | 36.7 M | 36.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 31 M | 31 M | 31 M | 31 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M |
Deferred Revenue |
3.95 M | 3.86 M | 3.48 M | 3.32 M | - | 3.4 M | 3.34 M | 6.03 M | 6.21 M | 6.22 M | 6.13 M | 6.17 M | 5.76 M | 5.65 M | 5.93 M | 5.96 M | 5.96 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | 5.25 M | 5.25 M | 5.25 M | 5.25 M | 5.16 M | 5.16 M | 5.16 M | 5.16 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.37 M | 5.37 M | 5.37 M | 5.37 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 9.12 M | 9.12 M | 9.12 M | 9.12 M | 8.31 M | 8.31 M | 8.31 M | 8.31 M | 6.52 M | 6.52 M | 6.52 M | 6.52 M | 5.76 M | 5.76 M | 5.76 M | 5.76 M |
Retained Earnings |
-278 M | -277 M | -276 M | -275 M | - | -272 M | -274 M | -272 M | -271 M | -267 M | -264 M | -260 M | -257 M | -253 M | -249 M | -247 M | -244 M | -242 M | -242 M | -242 M | -242 M | -224 M | -224 M | -224 M | -224 M | -211 M | -211 M | -211 M | -211 M | -202 M | -202 M | -202 M | -202 M | -188 M | -188 M | -188 M | -188 M | -178 M | -178 M | -178 M | -178 M | -145 M | -145 M | -145 M | -145 M | -144 M | -144 M | -144 M | -144 M | -136 M | -136 M | -136 M | -136 M | -127 M | -127 M | -127 M | -127 M |
Total Assets |
39.5 M | 37.5 M | 37.1 M | 38.9 M | - | 41.4 M | 45.8 M | 44.8 M | 47.5 M | 51.7 M | 55.4 M | 58.4 M | 58.8 M | 62.2 M | 65.7 M | 66.6 M | 75.5 M | 55.6 M | 55.6 M | 55.6 M | 55.6 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 93.8 M | 93.8 M | 93.8 M | 93.8 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 60 M | 60 M | 60 M | 60 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M |
Cash and Cash Equivalents |
20 M | 17.2 M | 18.8 M | 20.4 M | - | 21.7 M | 19 M | 19 M | 19.7 M | 21.3 M | 24.6 M | 27.2 M | 29.8 M | 34.3 M | 35.8 M | 37.9 M | 46.9 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 8.58 M | 8.58 M | 8.58 M | 8.58 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 4.58 M | 4.58 M | 4.58 M | 4.58 M |
Book Value |
30.8 M | 28.7 M | 29.4 M | 31 M | - | 33.4 M | 31 M | 30.2 M | 31.7 M | 34.9 M | 37.7 M | 41 M | 43.8 M | 46.5 M | 49.8 M | 51 M | 53.4 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 6.9 M | 6.9 M | 6.9 M | 6.9 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 25 M | 25 M | 25 M | 25 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M |
Total Shareholders Equity |
30.8 M | 28.7 M | 29.4 M | 31 M | 32.5 M | 33.4 M | 31 M | 30.2 M | 31.7 M | 34.9 M | 37.7 M | 41 M | 43.8 M | 46.5 M | 49.8 M | 51 M | 53.4 M | 30.5 M | 30.5 M | 30.5 M | 30.5 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 6.9 M | 6.9 M | 6.9 M | 6.9 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 25 M | 25 M | 25 M | 25 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of iCAD, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 12.72 | 2.66 % | $ 204 M |  USA |
 |
Evolent Health
EVH
|
$ 3.61 | 4.34 % | $ 412 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.36 | 2.44 % | $ 1.2 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.76 | 0.57 % | $ 123 M | USA |
 |
HealthEquity
HQY
|
$ 91.55 | 1.68 % | $ 7.89 B | USA |
 |
HealthStream
HSTM
|
$ 31.54 | 2.34 % | $ 947 M | USA |
 |
Omnicell
OMCL
|
$ 34.64 | 3.1 % | $ 1.59 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 8.72 | 1.75 % | $ 162 M | USA |
 |
Progyny
PGNY
|
$ 25.86 | 2.5 % | $ 2.2 B | USA |
 |
Phreesia
PHR
|
$ 10.37 | 2.88 % | $ 619 M | USA |
 |
Schrödinger
SDGR
|
$ 32.6 | 7.56 % | $ 2.39 B | USA |
 |
So-Young International
SY
|
$ 2.74 | 0.36 % | $ 213 M |  China |
 |
Teladoc Health
TDOC
|
$ 5.79 | 4.89 % | $ 1.02 B | USA |
 |
10x Genomics
TXG
|
$ 97.74 | 4.53 % | $ 12.2 B | USA |
 |
Veeva Systems
VEEV
|
$ 283.45 | 3.7 % | $ 46.4 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.91 | 3.24 % | $ 6.53 M | China |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |